Khunti and colleagues discuss the possible association between ethnicity and severity of covid-19.1 Our experience in London would […]

Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, […]

Genetic ‘barcoding’ in GP surgeries can identify men at higher risk of prostate cancer, researchers claim

The NHS Race and Health Observatory will be hosted by the NHS Confederation

The trial is unlikely to show a statistically significant improvement in invasive disease-free survival

The vaccine could be Janssen’s first to win EU approval

Breast cancer is the most common cancer in women. But individual tumors can vary significantly, presenting different spatial […]

The ongoing COVID-19 pandemic has severely impacted the manufacturing and supply chains for many products. But while shortages […]

ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab? chelfand Sun, 05/31/2020 – 16:58

ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data chelfand Sun, 05/31/2020 – 14:03